Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter brands (OTC’s) and biosimilar products for patients around the world.
The company has commercial operations in 35 countries with 2,800 employees and operates five manufacturing and development hubs in the U.S., Romania, Korea and Taiwan.
Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.
Alvogen's lines of business include: product development, contract manufacturing and research (CMO), and sales of generic medicines (Gx and Hx), biosimilars and OTC’s.
Alvogen's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology in addition to a fast growing portfolio of biosimilars and OTC products.
Our vision is to become the Preferred Partner by setting a new standard for the future of pharma. Five main pillars support our ambitious growth strategy and are the foundation for the Alvogen Starmap, which serves as the framework for our focus areas and the actions that are needed to become a global leader.
Alvogen has commercial operations in more than 30 countries, with regional hubs, manufacturing and R&D capabilities in the U.S., South Korea and Romania.
Alvogen has 350 generic products on the market, with over 200 strategically selected development projects in the pipeline. Connect with local teams to learn more about product offering in your region.